Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
3Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Corvus Pharmaceuticals, Inc. (CRVS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
3Distinct source URLs
6High confidence
0.791Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Corvus Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
ANGEL-PHARMACEUTICALS
ANGEL-PHARMACEUTICALS
90%
The Company’s ownership interest in Angel Pharmaceuticals was approximately 49.7 %, excluding 7 % of Angel Pharmaceuticals’ equity reserved for issuance under the Angel Pharmaceuticals Employee Stock…
JEFFERIES-LLC
JEFFERIES-LLC
90%
Jefferies is not required to sell any specific number or dollar amount of shares of the Common Stock, but has agreed, subject to the terms and conditions of the Amended Sales Agreement, to use its co…
SNYNF
Sanofi
72%
zed clinical trial in order to prioritize the development of our other two lead product candidates. Angel Pharmaceuticals is continuing the development of mupadolimab in China. Manufacturing We do no…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from CRVS graph: zed clinical trial in order to prioritize the development of our other two lead product candidates. Angel Pharmaceut…
Corvus Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
ompanies in our market sector; ● regulatory approval of soquelitinib, ciforadenant, mupadolimab and our other product candidates, or limitations to specific label indications or patient populations f…
EQUITY-METHOD-INVESTMENT-ANGEL-PHARMACEUTICALS-C
EQUITY-METHOD-INVESTMENT-ANGEL-PHARMACEUTICALS-C
62%
ent operations and the remaining maturity by type of security is as follows (in thousands): Maturities by Period at Amortized Cost Less than Total …
R-D-LIMITED
R-D-LIMITED
62%
% of Angel Pharmaceuticals’ equity reserved for issuance under the Angel Pharmaceuticals Employee Stock Ownership Plan, and is accounted for as an equity method investment. The Company recognized its…
Corvus Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CRVS-DEBT-8874
Warrants outstanding: 8934000
90%
xbrl warrant detail from xbrl 2025-12-31.
CRVS-DEBT
Debt stack $834,000
90%
Market cache reports total debt of $834,000.
CRVS-DEBT-8875
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Corvus Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Corvus Pharmaceuticals, Inc..
Corvus Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
CRVS-OWNER-ORBIMED-ADVISORS-LLC
ORBIMED ADVISORS LLC
90%
13F overlay lists ORBIMED ADVISORS LLC as top holder; 167 tracked holders.
Corvus Pharmaceuticals, Inc. Extended Supply Chain Network
